Pareto task inference analysis reveals cellular trade-offs in diffuse large B-Cell lymphoma transcriptomic data

Jonatan Blais1, Julie Jeukens2

  • 1Oncology Research Axis, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.

PubMed

Insights

Identifying cellular trade-offs can prevent cancer treatment resistance. This study found specific gene expression patterns in diffuse large B-cell lymphoma (DLCBL) linked to these trade-offs, offering new therapeutic targets.

Area of Science:

  • Cancer Biology
  • Systems Biology
  • Genomics

Background:

  • Cancer treatment resistance arises from selecting treatment-resistant clones.
  • Cellular trade-offs present vulnerabilities that could prevent resistance emergence.
  • Pareto optimality theory offers a framework to identify biological trade-offs.

Purpose of the Study:

  • To apply Pareto optimality theory to identify cellular trade-offs in cancer.
  • To analyze diffuse large B-cell lymphoma (DLCBL) transcriptomic data for phenotypic patterns.
  • To uncover potential therapeutic strategies by targeting identified trade-offs.

Main Methods:

  • Analysis of DLCBL transcriptomic data.
  • Application of Pareto optimality theory to gene expression data.
  • Identification of geometrical patterns (polytopes) in gene expression space.
  • Statistical analysis to confirm pattern significance.

Main Results:

  • Statistically significant evidence of a tetrahedron pattern in DLCBL gene expression data.
  • Identification of four specialized phenotypes (archetypes) represented by the tetrahedron's vertices.
  • Archetypes showed enrichment in specific biological functions and distinct gene expression patterns.
  • Results suggest trade-offs between energy production/protein synthesis and immune tolerance/escape.

Conclusions:

  • The study identified specific gene expression patterns indicative of cellular trade-offs in DLCBL.
  • These trade-offs likely involve energy metabolism, protein synthesis, and immune response strategies.
  • Simultaneously targeting genes on opposite sides of these trade-offs presents a promising therapeutic approach for DLCBL.